Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials
<p>Abstract</p> <p>Background</p> <p>In this meta-analysis we aimed to determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPC) for patients with advanced gastric cancer who underwent gastrectomy.</p> <p>Methods</p> &l...
Main Authors: | Sun Jingxu, Song Yongxi, Wang Zhenning, Gao Peng, Chen Xiaowan, Xu Yingying, Liang Jiwang, Xu Huimian |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2407/12/526 |
Similar Items
-
OUR EXPERIENCE OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR PATIENTS WITH ADVANCED GASTRIC CANCER
by: A. D. Kaprin, et al.
Published: (2016-01-01) -
Lobaplatin in Prophylactic Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer: Safety and Efficacy Profiles
by: Zhong Y, et al.
Published: (2020-06-01) -
Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Central‐Eastern European study
by: Roman Yarema, et al.
Published: (2019-06-01) -
Current Situation of Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinoma
by: ZHAN Hongjie, et al.
Published: (2021-04-01) -
Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure
by: Joji Kitayama, et al.
Published: (2014-01-01)